Alloy
Publishes more about its formulas than almost anyone here — concentrations, full ingredient lists, results labelled by measurement method — across four pages that between them contain no safety information at all, under four headings that promise it.
MODEL
Online intake reviewed by a menopause-trained physician, compounded and manufactured prescriptions delivered, with unlimited doctor access included.
The brand verdict
Six products assessed. Alloy is a menopause company that also sells skincare, and that framing produces the best-argued rationale we have read. Skin ageing after menopause is substantially an estrogen-deficiency problem — roughly 30% of dermal collagen goes in the first five years — and almost nothing on the market treats it as one. M4 does, with topical estriol.
Two disclosures put it ahead of the field. The full ingredient list is published on the product page, which four compounding competitors refuse to do. And the efficacy claim rests on a stated placebo-controlled trial rather than the day-30 satisfaction surveys the rest of this category runs on. A control arm and a significance test is a different order of claim.
Then the page stops. It has a tab headed 'Safety Information' that contains a product description and an ingredient list and nothing else. Side effects, contra-indications, pregnancy and breast cancer each appear zero times, on a prescription estrogen sold specifically to women in perimenopause and menopause — the population in which hormone-sensitive cancer is most common and in which estrogen exposure is sometimes the thing being actively suppressed.
Two further gaps. The absorption reassurance is phrased more absolutely than the evidence supports and contradicts the product's own collagen mechanism: estriol cannot both stay on the surface of the skin and reach dermal fibroblasts. And estriol has no FDA-approved form in the United States, so M4 is compounded by definition — a word Alloy applies plainly to three weight-loss drugs one menu away and never to this.
- Publishes the full ingredient list on the product page — complete and INCI-style, which four compounding competitors decline to do.
- Bases its efficacy claim on a stated placebo-controlled trial rather than an uncontrolled satisfaction survey.
- Cites the menopausal collagen-loss figures accurately.
- Treats the actual cause of menopausal skin change rather than its surface symptoms.
- A twelve-week timeline that matches the trial window instead of undercutting it.
- Real prescription gating with a menopause-trained physician reviewing medical history.
- $50 a month including unlimited doctor access, free delivery and HSA/FSA eligibility.
- States that the product can be used alongside HRT, which the controlled data supports.
- Names a medical team and cites ACOG and The Menopause Society as the guidance it follows.
The range
- R-332026-07-28
Rosacea Face Cream Rx
AZELAIC 17% + METRONIDAZOLE 1.11% + IVERMECTIN 0.88%All three first-line rosacea topicals in one anhydrous, preservative-free, airless-pumped base, with every concentration published and the actuator volume given to a tenth of a millilitre. It is the best-made compounded product in this register. Nobody has ever trialled the combination, one active sits below its approved strength, and the page still does not say how often to use it.
CONDITIONAL$33 PER MONTH
- R-322026-07-28
Lash & Brow Serum Rx
BIMATOPROST 0.03% — GENERIC LATISSEThe best page Alloy publishes and the only one that is not compounded: an FDA-approved generic named against its brand, at its approved concentration, with a real fill size and the first citations this company has printed. Two problems — the three-month supply is ten weeks by the manufacturer's own applicator count, and the periorbital fat atrophy on the approved label is mentioned nowhere.
CONDITIONAL$58 PER MONTH
- R-302026-07-28
M4 Eye Cream Rx
ESTRIOL 1% + PEPTIDESThe most completely specified product in this register — estriol 1%, palmitoyl pentapeptide-4 0.1%, acetyl hexapeptide-8 0.1%, a full ingredient list, and results labelled by whether an instrument or an assessor produced them. It is also five times the concentration of Alloy's body cream, applied to the thinnest skin on the face, millimetres from the meibomian glands, with no ophthalmic guidance of any kind.
CAUTION$30 PER MONTH
- R-282026-07-28
M4 Face Cream Rx
TOPICAL ESTRIOLA prescription estrogen cream for menopausal skin, with a full ingredient list published and a placebo-controlled trial claimed — both firsts here. It also has a section headed 'Safety Information' that contains no safety information: no side effects, no contra-indications, no pregnancy note, and no mention of breast cancer on a page selling topical estrogen to women over fifty.
CAUTION$50 PER MONTH
- R-312026-07-28
Tretinoin Face Cream Rx
TRETINOIN + NIACINAMIDE + ALOE · THREE UNNAMED STRENGTHSThe first Alloy product to publish a fill weight and a dose — 30 grams, a pea-sized amount nightly — which finally makes one of their supply claims checkable. It is also a teratogen-class topical sold to perimenopausal women with no pregnancy warning, no side effects, no sunscreen instruction, and three strengths of which none is named.
CAUTION$30 PER MONTH
- R-292026-07-28
M4 Body Treatment Rx
ESTRIOL 0.2% + PEPTIDESThe concentration is published here — estriol 0.2% — along with the full ingredient list and the study's sample size. All three are improvements on the face cream. But this one goes on chest, arms and legs, and the page says nothing at all about absorption, dose per application, or who should not use it.
CAUTION$65 PER MONTH
What repeats across the range
These are the findings a single review cannot make. Each one appears in more than one product, and each is drawn from the reviews above rather than from an impression of the brand.
- 01
A section headed Safety Information, containing none
The product page's third tab is labelled 'Safety Information'. Under it: what the product is, the ingredient list, who it is for, what you receive, and how to get a prescription. Searched across the whole page, side effects appear zero times, contra-indications zero, pregnancy zero and breast cancer zero. The failure is not that safety copy is missing; it is that it is missing from the place explicitly promising it.
- 02
The rationale is the best in the register and the citation is absent
Menopausal collagen loss is cited accurately — about 30% in five years, then 2.1% a year — and the efficacy claim is placebo-controlled at twelve weeks, which no competitor matches. But the study is credited to nobody: no journal, authors, year, sample size or link. And '88% improvement in elasticity' never says whether that is 88% of subjects or an 88% change.
- 03
An absorption claim stronger than the evidence, and than the mechanism
'Topical estriol stays on the surface of your skin and doesn't enter your bloodstream.' The conclusion it supports — no impact on blood estrogen levels — is defensible; controlled facial trials measured serum FSH, prolactin and estradiol and found no significant change. The mechanism as stated is not: a molecule that stayed on the surface could not reach the dermal fibroblasts the product claims to stimulate. 'No measurable change in serum levels' and 'does not enter the bloodstream' are different statements.
- 04
Instruments were run, and only sometimes reported
The body study used Corneometer, Moisturemeter EpiD, Cutometer and Antera 3D and published only the questionnaire: 97% agree, 95% felt, 84% saw, 79% saw. The eye product runs the same four instruments on n=34 and does it properly — 'up to 40% more elasticity' and 'up to 40% less crepiness on the eyelids' marked Based on Expert Assessment, '23% immediate boost in hydration' marked Based on Instrumentation. Labelling results by method is the best evidential practice in this register, and the same company omits it one product away.
- 05
The strongest concentration is on the most permeable skin
Estriol runs 1% in the eye cream, 0.2% in the body treatment, and unstated in the face cream. The controlled facial trials underpinning the line's safety case used 0.3%. So the highest strength in the range goes on periorbital skin — the thinnest and most permeable on the face — at more than three times the studied concentration, with no rationale offered. The mitigation is real and unstated: the eye area is tiny, so absolute exposure is probably the range's smallest.
- 06
The formulation work is better than the instructions
The rosacea cream is the best-made compounded product in this register: an anhydrous silicone and ester base, so no preservative is needed and none is present — a real advantage on skin most likely to react to one — with two penetration enhancers appropriate to delivering azelaic acid from a waterless vehicle, an airless pump, and a published 0.3 ml actuator volume that nothing else here provides. It then states no application frequency and no bottle size, so the most precise dose figure in the register cannot be turned into a daily dose. Every Alloy page arrives one number short of a claim you could check.
- 07
The one product they do not compound is the one that scores
Four compounded preparations score 58, 59, 59 and 65. The Lash & Brow Serum — generic Latisse, bimatoprost 0.03% — scores 69, states its FDA approval accurately, names its brand equivalent, publishes its concentration and its 5 ml volume, and carries the company's first citations. None of that required extra diligence: dispensing an approved drug means the manufacturer has already established the facts, and the page's job shrinks to not contradicting them.
- 08
Every page discloses a different subset, and none discloses safety
The eye cream publishes three concentrations, a full ingredient list and results attributed to measurement method. The body treatment publishes one concentration and a full list. The tretinoin cream publishes a 30 g fill weight and a pea-sized dose — the only Alloy claim we have been able to verify arithmetically — and no concentration for any of its three strengths. The face cream publishes a list and nothing else. No page supplies more than three of six basic disclosures, no two supply the same three, and all four Safety Information sections contain a product description.
- 09
A retinoid sold to women who can still conceive, with nothing said
The tretinoin page contains zero mentions of pregnancy, breastfeeding, contraception or birth defects, and zero of irritation, peeling or sunscreen. Alloy sells exclusively to perimenopausal and menopausal women; perimenopause means ovulation continues and contraception is still advised. Topical tretinoin is a far lower risk than the oral drug and the honest warning is proportionate rather than alarming — which is what makes its complete absence harder to explain, not easier.
- 10
Facial evidence, body application
The line's no-systemic-effect reassurance rests on trials that applied estriol to faces. The body treatment is indicated for chest, legs, arms, hands and knees. Concentration is not exposure — 0.2% over a third of the skin delivers considerably more hormone than 0.3% on a face — and the body page makes no absorption statement at all, gives no application quantity and no fill size. Alloy sells estradiol gel one menu away as systemic HRT, applied to arms and thighs, so transdermal body application is a route the company uses deliberately elsewhere.
- 11
Compounded, and the word appears everywhere except here
No FDA-approved estriol product exists in the United States, so M4 is necessarily compounded. The page says 'prescription', 'bioidentical' and 'plant based', never 'compounded' — while Alloy's own navigation lists Compounded Semaglutide, Compounded Tirzepatide and Compounded Liraglutide. The company also states its physicians follow ACOG guidance, and ACOG's clinical consensus on compounded bioidentical hormone therapy is cautionary.
Disclosure scorecard
Not what is in the product — what the company publishes about it, and where. “Findable” means the concentration exists somewhere, such as a help-centre article, rather than on the page you buy from.
SCROLL THE TABLE SIDEWAYS
| PRODUCT | CONC. ON PAGE | CONC. FINDABLE | CONTRA-INDICATIONS | SIZE | SIDE EFFECTS |
|---|---|---|---|---|---|
| Rosacea Face Cream Rx | YES | YES | NO | NO | NO |
| Lash & Brow Serum Rx | YES | YES | NO | YES | NO |
| M4 Eye Cream Rx | YES | YES | NO | NO | NO |
| Tretinoin Face Cream Rx | NO | NO | NO | YES | NO |
| M4 Body Treatment Rx | YES | YES | NO | NO | NO |
| M4 Face Cream Rx | NO | NO | NO | NO | NO |
If you buy one
Rosacea Face Cream Rx
Worth buying for a specific person with a specific problem. Read who.
M4 Body Treatment Rx
There is a real reason to hesitate. Read the finding before you buy.